There is no evidence of the JAK2 V617F point mutation by real-time PCR analysis. This result does not entirely exclude the possibility that a JAK2 V617F mutation is present below the test limit of detection (0.2 percent).

This result has been reviewed and approved by Anna Matynia, M.D.

**Background Information:** JAK2 Gene, V617F Mutation, Quantitative

**Test Information:**
This assay is designed to detect the point mutation c.1849G>T (V617F) of the JAK2 gene. JAK2 V617F mutations are present in patients with myeloproliferative neoplasms.

**Methodology:**
DNA is isolated from granulocyte enriched whole blood. Quantitative allele specific real-time PCR is then performed with primers to exon 14 of the JAK2 gene to detect the mutation.

**Limitations:**
Mutations in other locations within the JAK2 gene or in other genes will not be detected. The limit of detection for this assay is 0.2 percent mutant allele to normal allele.

Results of this test must always be interpreted within the clinical context and other relevant data, and should not be used alone for a diagnosis of malignancy. This test is not intended to detect minimal residual disease.

Test developed and characteristics determined by ARUP Laboratories. See Compliance Statement B: aruplab.com/CS

**Patient: Example**

**DOB:**

**Gender:**

**Patient Identifiers:** 01234567890ABCD, 012345

**Visit Number (FIN):** 01234567890ABCD

**Collection Date:** 00/00/0000 00:00
## VERIFIED/REPORTED DATES

<table>
<thead>
<tr>
<th>Procedure</th>
<th>Accession</th>
<th>Collected</th>
<th>Received</th>
<th>Verified/Reported</th>
</tr>
</thead>
<tbody>
<tr>
<td>JAK2 Gene, V617F Mutation, Quantitative</td>
<td>19-179-402657</td>
<td>00/00/0000 00:00</td>
<td>00/00/0000 00:00</td>
<td>00/00/0000 00:00</td>
</tr>
</tbody>
</table>

END OF CHART

H=High, L=Low, *=Abnormal, C=Critical